Mednet Logo
SpecialtiesMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

If a patient with non-metastatic prostate cancer is found to have a BRCA mutation, should this influence treatment recommendations for local therapy?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

While there are no randomized trials to address this question, one prospective, non-randomized study of BRCA2 carriers with localized prostate cancer suggested improved outcomes with lower relapse rates in men treated with radical prostatectomy as opposed to radiation therapy. See: Castro et al., Jo...

For unfavorable intermediate prostate cancer in elderly patients, would you consider radiation without ADT?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

This is a great and highly clinically relevant question that I view has 4 important inter-related points.First, I will take the liberty of rephrasing the question as I believe the real question is... for a man with a good enough life expectancy to warrant curative intent RT, does age and comorbid co...

When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?

10
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Minnesota–Masonic Cancer Center

There is no right or wrong answer here. The Johns Hopkins approach is to always recommend a clinical trial for the nonmetastatic BCR population. In the absence of a trial, our group does not believe that early ADT is justified in men with PSADT >9 months, where metastasis-free survival approaches 10...

How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Nebraska Medical Center

My modifications based off the GRIFFIN trial (Voorhees et al., PMID 32325490) are as follows: If patients have high burden disease and no underlying neuropathy, I will start with twice-weekly bortezomib (days 1, 4, 8, 11) but will change the dexamethasone to 20 mg days 1, 4, 8, 11, and 15 using the ...

How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Nebraska Medical Center

My modifications based off the GRIFFIN trial (Voorhees et al., PMID 32325490) are as follows: If patients have high burden disease and no underlying neuropathy, I will start with twice-weekly bortezomib (days 1, 4, 8, 11) but will change the dexamethasone to 20 mg days 1, 4, 8, 11, and 15 using the ...

For those rare patients now out 5 years post GBM treatment and continuous Optune, is there a point one would stop Optune?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

I haven’t seen any data from Optune on these very long term survivors. They have released some subset data that patients who used the device 90% of the time or greater had a 29% chance of being alive at 5 years which is pretty remarkable. Certainly think there are diminishing returns beyond 5 years....

How do you approach the management of a patient with lumbar spinal metastasis with neurologic symptoms but without evidence of spinal cord compression?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arizona

From the brief description included, it appears that the lesion is at the level of the cauda equina, a group of nerves and nerve roots stemming from the distal end of the spinal cord, typically levels of L1-L5, and contains axons of nerves that give both motor and sensory innervation to the legs, bl...

What criteria do you use to decide whether to start anticonvulsants in patients with brain metastases?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

Patients with intact brain metastases in the absence of seizure activity should generally not be receiving prophylactic anticonvulsants based on 2019 guidelines from the Congress of Neurologic Surgeons subsequently endorsed by SNO and ASCO. The practice of prophylactic AEDs in the post-op setting is...

How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?

1
1 Answers

Mednet Member
Mednet Member
Neurology · MD Anderson Cancer Center

As soon as possible. The diagnostic yield of biopsy or LP can diminish very quickly after steroid initiation. Holding steroids for 7-10 days if possible is one common strategy to try to mitigate this. If steroids are unavoidable, or if tapering/holding them is not feasible, additional strategies to ...

How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?

1
1 Answers

Mednet Member
Mednet Member
Neurology · MD Anderson Cancer Center

As soon as possible. The diagnostic yield of biopsy or LP can diminish very quickly after steroid initiation. Holding steroids for 7-10 days if possible is one common strategy to try to mitigate this. If steroids are unavoidable, or if tapering/holding them is not feasible, additional strategies to ...